S. GÜR Et Al. , "IVABRADINE (FIRST HCN CHANNEL BLOCKER) ATTENUATES HUMAN CORPUS CAVERNOSUM CONTRACTION IN VITRO VIA INTERFERENCE WITH THE CALCIUM AND POTASSIUM TRANSFER: A POTENTIAL NEW THERAPEUTIC OPTION FOR ERECTILE DYSFUNCTION," American-Urological-Association(AUA) Annual Meeting , vol.199, San-Francisco, Costa Rica, 2018
GÜR, S. Et Al. 2018. IVABRADINE (FIRST HCN CHANNEL BLOCKER) ATTENUATES HUMAN CORPUS CAVERNOSUM CONTRACTION IN VITRO VIA INTERFERENCE WITH THE CALCIUM AND POTASSIUM TRANSFER: A POTENTIAL NEW THERAPEUTIC OPTION FOR ERECTILE DYSFUNCTION. American-Urological-Association(AUA) Annual Meeting , (San-Francisco, Costa Rica).
GÜR, S., Alzweri, L., Abdel-Mageed, A., Sikka, S., Kadowitz, P., & Hellstrom, W., (2018). IVABRADINE (FIRST HCN CHANNEL BLOCKER) ATTENUATES HUMAN CORPUS CAVERNOSUM CONTRACTION IN VITRO VIA INTERFERENCE WITH THE CALCIUM AND POTASSIUM TRANSFER: A POTENTIAL NEW THERAPEUTIC OPTION FOR ERECTILE DYSFUNCTION . American-Urological-Association(AUA) Annual Meeting, San-Francisco, Costa Rica
GÜR, SERAP Et Al. "IVABRADINE (FIRST HCN CHANNEL BLOCKER) ATTENUATES HUMAN CORPUS CAVERNOSUM CONTRACTION IN VITRO VIA INTERFERENCE WITH THE CALCIUM AND POTASSIUM TRANSFER: A POTENTIAL NEW THERAPEUTIC OPTION FOR ERECTILE DYSFUNCTION," American-Urological-Association(AUA) Annual Meeting, San-Francisco, Costa Rica, 2018
GÜR, SERAP Et Al. "IVABRADINE (FIRST HCN CHANNEL BLOCKER) ATTENUATES HUMAN CORPUS CAVERNOSUM CONTRACTION IN VITRO VIA INTERFERENCE WITH THE CALCIUM AND POTASSIUM TRANSFER: A POTENTIAL NEW THERAPEUTIC OPTION FOR ERECTILE DYSFUNCTION." American-Urological-Association(AUA) Annual Meeting , San-Francisco, Costa Rica, 2018
GÜR, S. Et Al. (2018) . "IVABRADINE (FIRST HCN CHANNEL BLOCKER) ATTENUATES HUMAN CORPUS CAVERNOSUM CONTRACTION IN VITRO VIA INTERFERENCE WITH THE CALCIUM AND POTASSIUM TRANSFER: A POTENTIAL NEW THERAPEUTIC OPTION FOR ERECTILE DYSFUNCTION." American-Urological-Association(AUA) Annual Meeting , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={SERAP GÜR Et Al. }, title={IVABRADINE (FIRST HCN CHANNEL BLOCKER) ATTENUATES HUMAN CORPUS CAVERNOSUM CONTRACTION IN VITRO VIA INTERFERENCE WITH THE CALCIUM AND POTASSIUM TRANSFER: A POTENTIAL NEW THERAPEUTIC OPTION FOR ERECTILE DYSFUNCTION}, congress name={American-Urological-Association(AUA) Annual Meeting}, city={San-Francisco}, country={Costa Rica}, year={2018}}